Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib and Gefitinib in EGFR-mutated NSCLC
NCT02025114Phase 2Completed
- Sponsor
- National Taiwan University Hospital
- Start
- Sep 2014
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of selumetinib in non-small cell lung cancer (NSCLC), sponsored by National Taiwan University Hospital. Started Sep 2014; status: completed.
02
Drugs
selumetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02025114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02025114.